

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ZZ-83) RALIMETINIB


PRONUNCIATION ral'' i me' ti nib

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. 3*H*-Imidazo[4,5-*b*]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1*H*-imidazol-5-yl]-3-(2,2-dimethylpropyl)-
2. 5-(2-(*tert*-butyl)-4-(4-fluorophenyl)-1*H*-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine
3. 5-[2-*tert*-butyl-5-(4-fluoro-phenyl)-1*H*-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3*H*-imidazo[4,5-*b*]pyridin-2-ylamine

STRUCTURAL FORMULA

MOLECULAR FORMULA C₂₄H₂₉FN₆

MOLECULAR WEIGHT 420.5

TRADEMARK None as yet

SPONSOR Eli Lilly and Company

CODE DESIGNATIONS LY22288220

CAS REGISTRY NUMBER 862505-00-8

WHO NUMBER 9753